POSITION PAPER ON TUBERCULOSIS SCREENING IN PATIENTS WITH IMMUNE MEDIATED INFLAMMATORY DISEASES CANDIDATES FOR BIOLOGICAL THERAPY
Abstract
Chronic immunosuppression is a known risk factor for tuberculosis. Our aim was to reach a consensus on screening and prevention of tuberculosis in patients with immune mediated inflammatory diseases candidates to biolo- gic therapy. Methods: Critical appraisal of the literature and expert opinion on immunosuppressive therapies and risk of tuberculosis. Results and Conclusion: The currently recommended method for screening is the tuberculin skin test and the interferon gamma assay, after exclusion of active tuberculosis. Positively screened patients should be treated for la- tent tuberculosis infection. Patients may start biological therapy after 1 to 2 months, as long as they are strictly adhering to and tolerating their preventive regimen.
KEYWORDS – Latent tuberculosis; Immunologic factors; Biological therapy; Tumor necrosis factor-alpha; Immunosup- pressive agents; Immune system diseases.
Downloads
All articles in this journal are Open Access under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).